258501-33-6

Upstream product

• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 212061-25-1 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)oxy]ethyl]-5-methyluridine 
• 212061-26-2 2'-O-[(2-formadoxyiminooxy)ethyl]-5'-O-tert-butyldiphenylsilyl-5-methyluridine 
• 212061-24-0 5'-O-(tert-butyldiphenylsilyl)-2'-O-(2-hydroxyethyl)-5-methyluridine 
• 171763-19-2 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine 

Downstream Products

• 212061-27-3 5'-O-tert-butyldiphenylsilyl-2'-O-[N,N dimethylaminooxyethyl]-5-methyluridine 
• 258501-34-7 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[[N-methyl-N-(2-phthalimidoethyl)amino]oxy]ethyl]-5-methyluridine 
• 618097-70-4 5'-O-(tert-butyldiphenylsilyl)-2'-O-[2-[(N-isopropyl-N-methylamino)oxy]ethyl]-5-methyluridine 
• 618097-72-6 5'-O-(4,4'-dimethoxytrityl)-2'-O-[2-[(N-isopropyl-N-methylamino)oxy]ethyl]-5-methyluridine 
• 258501-36-9 5'-O-(4,4'-dimethoxytrityl)-2'-O-[2-[[N-methyl-N-(2-phthalimidoethyl)amino]oxy]ethyl]-5-methyluridine 
• 315701-92-9 N⁴-benzoyl-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-04-7 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methyluridine 
• 400821-05-8 3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 400821-06-9 N⁴-benzoyl-3',5'-O-bis(tert-butyldiphenylsilyl)-2'-O-{2-[(N,N-dimethylamino)oxy]ethyl}-5-methylcytidine 
• 212061-29-5 5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine 

Relevant academic research and scientific papers

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of PTPRA expression

Antisense compounds, compositions and methods are provided for modulating the expression of PTPRA. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTPRA. Methods of using these compounds for modulation of PTPRA expression and for treatment of diseases associated with expression of PTPRA are provided.

Antisense modulation of Ran GTPase activating protein 1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of Ran GTPase activating protein 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ran GTPase activating protein 1. Methods of using these compounds for modulation of Ran GTPase activating protein 1 expression and for treatment of diseases associated with expression of Ran GTPase activating protein 1 are provided.

Antisense modulation of KIAA1531 protein expression

Antisense compounds, compositions and methods are provided for modulating the expression of KIAA1531 protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding KIAA1531 protein. Methods of using these compounds for modulation of KIAA1531 protein expression and for treatment of diseases associated with expression of KIAA1531 protein are provided.

Antisense modulation of G protein-coupled receptor 6 expression

Antisense compounds, compositions and methods are provided for modulating the expression of G protein-coupled receptor 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G protein-coupled receptor 6. Methods of using these compounds for modulation of G protein-coupled receptor 6 expression and for treatment of diseases associated with expression of G protein-coupled receptor 6 are provided.

Antisense modulation of PPP2R1A expression

Antisense compounds, compositions and methods are provided for modulating the expression of PPP2R1A. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PPP2R1A. Methods of using these compounds for modulation of PPP2R1A expression and for treatment of diseases associated with expression of PPP2R1A are provided.

Antisense modulation of LAR expression

Antisense compounds, compositions and methods are provided for modulating the expression of LAR. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding LAR. Methods of using these compounds for modulation of LAR expression and for treatment of diseases associated with expression of LAR are provided.

Antisense modulation of phosphotyrosyl phosphatase activator expression

Antisense compounds, compositions and methods are provided for modulating the expression of phosphotyrosyl phosphatase activator. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding phosphotyrosyl phosphatase activator. Methods of using these compounds for modulation of phosphotyrosyl phosphatase activator expression and for treatment of diseases associated with expression of phosphotyrosyl phosphatase activator are provided.

Antisense modulation of requiem expression

Antisense compounds, compositions and methods are provided for modulating the expression of requiem. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding requiem. Methods of using these compounds for modulation of requiem expression and for treatment of diseases associated with expression of requiem are provided.

Antisense modulation of hepatoma-derived growth factor expression

Antisense compounds, compositions and methods are provided for modulating the expression of hepatoma-derived growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding hepatoma-derived growth factor. Methods of using these compounds for modulation of hepatoma-derived growth factor expression and for treatment of diseases associated with expression of hepatoma-derived growth factor are provided.